In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

(2019) Katherine Young et al.   BMC MICROBIOLOGY

Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae

(2018) Krisztina M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , and Acinetobacter spp.

(2018) E. Matuschek et al.   CLINICAL MICROBIOLOGY AND INFECTION

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016

(2018) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

(2018) James A Karlowsky et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of Imipenem-Relebactam against Gram-Negative Bacilli from Global ICU and Non-ICU Wards — SMART 2015-2016

(2018) Sibylle H. Lob et al.   Journal of Global Antimicrobial Resistance

Activity of Imipenem-Relebactam against Pseudomonas aeruginosa with Antimicrobial-Resistant Phenotypes from Seven Global Regions—SMART 2015-2016

(2018) James A. Karlowsky et al.   Journal of Global Antimicrobial Resistance

AmpC β-lactamase induction by avibactam and relebactam

(2017) David M Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)

(2017) Michael A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace

(2017) Latania K. Logan et al.   JOURNAL OF INFECTIOUS DISEASES

Global Dissemination ofblaKPCinto Bacterial Species beyond Klebsiella pneumoniae andIn VitroSusceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam

(2016) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)

(2016) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The global epidemiology of carbapenemase-producing Enterobacteriaceae

(2016) David van Duin et al.   Virulence

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

(2015) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013

(2015) S.H. Lob et al.   Journal of Global Antimicrobial Resistance

Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)

(2014) Robert K. Flamm et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa

(2013) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY